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5-hydroxymethylcytosine (5-hmC) is a modiﬁed form of cytosine recently found in mammalians and is believed, like 5-methyl-
cytosine, to also play an important role in switching genes on and oﬀ. By utilizing a newly developed 5-hmC immunoassay, we
determined the abundance of 5-hmC in human tissues and compared 5-hmC states in normal colorectal tissue and cancerous
colorectal tissue. Signiﬁcant diﬀerences of 5-hmC content in diﬀerent tissues were observed. The percentage of 5-hmC measured
is high in brain, liver, kidney and colorectal tissues (0.40–0.65%), while it is relatively low in lung (0.18%) and very low in heart,
breast,andplacenta(0.05-0.06%).Abundanceof5-hmCinthecancerouscolorectaltissueswassigniﬁcantlyreduced (0.02–0.06%)
compared to that in normal colorectal tissues (0.46–0.57%). Our results showed forthe ﬁrst time that 5-hmC distribution is tissue
dependent in human tissues and its abundance could be changed in the diseased states such as colorectal cancer.
1.Introduction
DNA methylation is an epigenetic modiﬁcation which is
catalyzed by DNA cytosine-5-methyltransferases (DNMTs)
and occurs at the 5-position (C5) ofthe cytosine ring, within
CpG dinucleotides. DNA methylation is essential in regu-
lating gene expression in nearly all biological processes in-
cluding development, growth, and diﬀerentiation [1–3]. Al-
terations in DNA methylation have been demonstrated to
cause the changes in gene expression. For example, hyper-
methylation leadstogenesilencing ordecreased geneexpres-
sion while hypomethylation activates the genes or increases
gene expression. Region-speciﬁc DNA methylation is mainly
found in 5 -CpG-3  dinucleotideswithin the promotersorin
theﬁrst exonof genes, which is an important pathway for the
repression of gene transcription in diseased cells.
Very recently, a modiﬁed nucleotide, 5-hydroxymethyl-
cytosine (5-hmC) was detected to be abundant in mouse
brain and embryonic stem cells [4–6]. 5-hmC is a hydrox-
ylated and methylated form of cytosine and was ﬁrst seen in
bacteriophages in 1952 [7]. In mammals, it can be generated
by a TET protein-mediated reaction [5]. The exact function
of 5-hmC in epigenetics is still a mystery today. However,
a line of evidence showed that conversion of 5-mC to 5-
hmC greatly reduced aﬃnity of MBD proteins to methylated
DNA [8], and 5-hmC accounts for roughly 40 percent of the
methylated cytosine in Purkinje cells and is also speciﬁcally
localized in CpG regions [4]. Thus, 5-hmC might also play
an important and diﬀerent role in regulation of DNA meth-
ylation, chromatin remodeling, and gene expression in a
tissue-, cell-, or organ-speciﬁc manner.
Because of the presence of 5-hmC in DNA with unclear
functions in gene regulation and the discovery of the TET
enzymes that produce 5-hmC, it is considered necessary to
determine the distribution of this modiﬁed DNAbase in dif-
ferent human tissues. It would be particularly important
to identify the changes of 5-hmC abundance in diﬀerent
disease states in human tissues, which is necessary not only
for reevaluating the existing methylation datasets, but also
for gaining correct information on epigenetic regulation of
physiological and pathological process. Tissue distribution
of 5-hmC in mouse was described [9]. However, to our
knowledge, there is currently no information available about
the status of 5-hmC or hydroxymethylated DNA in human
tissues, speciﬁcally the distribution of 5-hmC in diﬀerent
tissues and its alterations in diseased states. By utilizing a 5-
hmC immunoassay recently developed by us, we quantiﬁed2 Journal of Nucleic Acids
the content of 5-hmC in human tissues and compared 5-
hmC states in normal colon tissue and cancerous colon
tissue.Wefoundthatthecontentof5-hmCvariesindifferent
human tissues and is signiﬁcantly decreased in cancer com-
pared to normal tissues.
2.Materialsand Methods
2.1. DNA Isolation from Tissue Samples and Cell Lines.
The following DNA samples were obtained from BioChain
(Hayward, Calif, USA): (1) frozen tissues of human brain,
lung, heart, liver, kidney, colorectum, and colorectal cancer;
(2) frozen tissues of mouse brain. The human placenta DNA
was obtained from Bioline (Taunton, Mass, USA). The
following DNA samples were prepared using FitAmp Blood
and Cultured CellDNAExtractionKit (Epigentek,NY, USA)
from Hela cervical cancer cell line, HCT116 colon cancercell
line, SW620 colon cancer cell line, and AN3CA endometrial
cancer cell line. The concentrations of all DNA samples are
measured with spectrophotometer and conﬁrmed with a
PicoGreen dsDNA quantitation kit (Invitrogen, Calif, USA).
A 260/280 ratio of all DNA samples is greater than 1.8.
2.2. Generation of Reference DNA Fragments Containing Cy-
tosine, 5-mC, and 5-hmC. DNA fragments containing cyto-
sine, 5-mC, or 5-hmC were ampliﬁed by PCR using a
region ofhMLH1containingpromoter andexon1.A starting
amount of 1ng of human placenta DNA was used to
generate 693 bp DNA amplicons by PCR reactions with
ar e a c t i o nb u ﬀer containing 0.2mM of each dNTP (or
5mdCTP or 5hmdCTP in place of dCTP) and Phire hot
start polymerase (Finnzymes, Mass, USA). PCR reactions in
20µL reaction volumes were carried out according to the
manufacturer’s instructions using the forward primer 5 -
GTCCAAGGCAAGAGAATAGG-3  and the reverse primer
5 -AGCCAATAGGAGCAGAGATG-3 .T oe ﬀectively remove
unmodiﬁed DNA templates from the ﬁnal products, subse-
quent PCR ampliﬁcations were performed using 1µLo fﬁ r s t
round PCR products in 20µL of reaction volume under the
same reaction conditions with diﬀerent primers to generate
357bp DNA products. These DNA products contain about
25% cytosine (umDNA), 25% 5-mC (mDNA), and 25% 5-
hmC (hmDNA), respectively. PCR products were then run
on a 1.5% agarose gel to conﬁrm the correct length and
puriﬁed by a sodium acetate/ethanol precipitation method.
2.3. 5-hmC Immunoassay. 200ng of DNA was mixed with
100µL of DNA binding solution and then added into the
assay wells of microplates. The solution was incubated at
37◦C for 90min to allow DNA binding onto the assay wells
tightly. The wells were washed 3 times with PBS-T, and anti-
5-hydroxymethylcytosine polyclonal antibody (Epigentek,
NY, USA)was added into the wells at 1µg/mL and incubated
at room temperature for 60min. After washing 3 times,
biotin-conjugated antirabbit antibody (Pierce) at 0.2µg/mL
was added and incubated at room temperature for 30min.
After washing with PBS-T 4 times, the signal enhancing
solution containing avidin-peroxidase complex was added
and incubated for 30min. After washing with PBS-T 4 times,
TMB (100µL per well) was added and incubated at room
temperature for 10min, and then 50µLo f1MH C lp e rw e l l
was added to stop the enzymatic reaction. The reference
DNA fragments containing 5-hmC and 5-mC were used as
the positive standard and negative control, respectively. The
absorbance end point (optical density, OD) was read on
a Max kinetic microplate reader (Molecular Devices, Calif,
USA). The amount of 5-hydroxymethylcytosine is propor-
tional to the OD intensity measured. After subtracting
negative control readings from the readings for the sample
and the standard, the value of 5-hydroxymethylcytosine for
each sample was calculated as a ratio of sample OD relative
to the standard OD.
2.4. 5-mC Quantiﬁcation. The content of 5-mC or methy-
lated DNA was quantiﬁed using a MethylFlash Methylated
DNA Quantiﬁcation Kit (Epigentek, NY, USA) according to
the manufacturer’s instruction.
2.5. Data Analysis. Data are reported below as mean ± SD.
Slope of the standard curve is determined using linear
r e g r e s s i o n ,a n dt h ep e r c e n t a g eo f5 - h m Ci nt h et o t a lD N A
is calculated using the following formula:
5-hmC% =
Sample OD − Negative Control OD
Slope × Input DNA Amount
× 100%.
(1)
3.Results
3.1. Sensitivity and Speciﬁcity of 5-hmC Immunoassay. To de-
termine if signal intensity isproportional totheamountof 5-
hmC in this immunoassay, the reference hmDNA fragments
were added in the assay wells at diﬀerent concentrations.
As shown in Figure 1(a), the OD values were increased
with the amount of hmDNA. Dose-response curve is linear
in the concentration range of 0.2ng to 10ng. To test the
sensitivity and speciﬁcity of the assay, diﬀerent amounts of
umDNA, mDNA, and hmDNA were used in the assay. The
results (Figure 1(b)) showed that the absorbance signal was
linearly increased with the input amount of hmDNA, and
ODvaluesweredetectedfromtheconcentrationpointaslow
as 0.1ng of hmDNA, while absorbance intensity generated
from umDNA and mDNA was not increased with increased
amount. Importantly, even if the amount of mDNA was
increasedto100ng,10-foldhigherthanthemaximalamount
of hmDNA, the absorbance intensity of mDNA is still at
the background level (blank control with no DNA). This
demonstrates that this assay allows discrimination between
5-hmC and 5-mC to be greater than 1:1000.
3.2. Distribution of 5-hmC in Diﬀerent Human Tissues and
Cell Lines. Utilizing this assay we determined the content of
5-hmC in diﬀerent human tissues and cell lines. DNA was
isolated from 9 normal human tissues of individuals aged
from 24 to 78 years old. These tissues include brain, lung,
breast, heart, kidney, placenta, breast, colon and rectum.Journal of Nucleic Acids 3
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Figure 1: Sensitivity and speciﬁcity determination of 5-hmC by the immunoassay. (a) Linear relationship between the absorbance and
amount of hmC-containinghmDNA reference fragment (b).
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Figure 2: Quantiﬁcation of 5-hmC and 5-mC in genomic DNA isolated from human tissues. (a) 5-hmC contents. The data are average
values ± standard deviation from 3 diﬀerent assays. (b) 5-mC contents. The data are average values ± standard deviation from 3 diﬀerent
assays.4 Journal of Nucleic Acids
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Figure3:Contentsof5-hmCand5-mCmeasured fromnormalcolonandcancerous colontissues.(a)5-hmCcontents.Thedataareaverage
values ± standard deviation from 3 diﬀerent assays. (b) 5-mC contents. The data are average values ± standard deviation from 3 diﬀerent
assays.
DNA was also isolated from 4 cell lines including Hela cervi-
cal cancer, ANCA3 endometrial cancer, HCT116 colon can-
cer, and SW620 colon, cancer cells. As shown in Figure 2(a),
signiﬁcant diﬀerences of 5-hmC content in diﬀerent tissues
were observed. For example, the percentage of 5-hmC
measured in brain is 0.67%, which is about 13-fold higher
than that in the heart (0.05%). It was also observed that
5-hmC was abundant in kidney (0.38 %), colon (0.45%),
rectum (0.57%), and liver (0.46%) tissues. In contrast, 5-
hmCcontentwasrelativelylowinlung(0.14%),andverylow
in breast (0.05%) and placenta (0.06%). Interestingly, little
5-hmC content was detected in all 4 cell lines (<0.02%). We
also measured the 5-hmC amount in mouse brain tissues.
The known 5-hmC content in mouse brains was reported
early [4, 6, 9, 10]. The amount of 5-hmC measured by our
assay in mouse brain was 0.15% of total DNA, which is sim-
ilar to that analyzed by LC-MS (0.13–0.15% of total DNA)
[6, 9] or by radioactive hmC glucosylation assay (0.24% of
total DNA) [10]. Thus, this result would provide supporting
evidence to indicate that the 5-hmC contents measured in
human tissues are accurate. We further measured the 5-mC
contents in these tissues in order to compare the 5-mC and
5-hmC distribution patternsin thesame tissues. As shown in
Figure 2(b),the5-mCcontentofalltissuesrangedfrom0.6%
to 1.5%, which makes the diﬀerencesof the 5-mC amount in
these tissues be only 1- to 2.5-fold. Similarly, the diﬀerences
of 5-mC amount in 4 the cell lines are also not signiﬁcant
(0.8%–1.6%).
3.3. 5-hmC Is Decreased in Cancerous Tissues. Because
tissues-speciﬁc distribution of 5-hmC was observed, it is
interesting to determine if 5-hmC content will be changed
when tissue/cells are in diseased states such as cancer. We
thus quantiﬁed the 5-hmC content in cancerous colorectal
tissues from two individuals with moderately diﬀerentiated
colon or rectal carcinoma. Compared to 5-hmC contents of
normal colon and rectal tissues (0.46% and 0.57%, resp.),
the percentage of 5-hmC in colon cancer and rectal cancer
measured was 7.7-fold (0.06%) and 28-fold (0.02%) less,
respectively. To further conﬁrm if 5-hmC is really decreased
in cancerous colorectal tissues, we examined the 5-hmC
contents in another colon cancer (moderately diﬀerentiated)
and the matched adjacent normal colon tissues from a 56-
year-old individual. The results showed that the percentage
of 5-hmC in cancerous tissue was only 0.025%. In contrast,
5-hmC content was 4.4 times more (0.11%) in adjacent
normal colon tissue, though it was still much less than
that obtained from normal colorectal tissues from healthy
individuals (Figure 3).
4.Discussion
In thisstudy, we described the distribution of 5-hmC in vari-
oushumantissues.Unlikethecontentof5-mC,which isonly
1–2.5-fold diﬀerent in tested human tissues, 5-hmC content
showed a 13-fold greater diﬀerence in diﬀerent tissues.
Brain tissue contains the highest level of 5-hmC, and liver,
colorectum and kidney present relatively high abundance of
5-hmC. Generation of 5-hmC in mouse cells was believed
to be mainly due to an enzymatic conversion of 5-mC to
5-hmC by TET1 protein or TET protein family [5, 11]. 5-
hmC contents in mouse ES cells seem also corrected with
expression of TET protein family (TET1-3) [10]. However,
tissue-speciﬁc distribution of 5-hmC in human tissues that
we observedmay not beexplained only bythis mechanism asJournal of Nucleic Acids 5
TET proteins were strongly expressed in heart and placenta
tissues that contain extremely low 5-hmC amount; and there
was no correlation between high 5-hmC content and low 5-
mC level in each type of tissue. The mechanisms of tissue-
speciﬁc distributions of 5-hmC in human tissues still need
further exploration.
It is particularly interesting to ﬁnd that 5-hmC is sig-
nificantly reduced in cancerous colorectal tissues and even
decreased to an undetectable level in colon cancer cell lines.
The detection with increased samples (38 colon cancer
tissuesand8normalcolontissues)furtherconﬁrmed5-hmC
content in colon cancer is 4-fold lower than that in normal
colon tissues (data not shown). These results suggested that
5-hmC may negatively regulate cancer formation and devel-
opment at least in colorectal tissues. Numerous evidences
showed that methylation-mediated silencing of tumor sup-
pression and apoptosis genes is involved in cancer forma-
tion and progression. 5-hmC has been shown to prevent
DNA methylation by blocking the maintenance DNA meth-
yltransferase (DNMT1) from methylating DNA containing
5-hmC [12]and involvesthemaintenance ofgeneexpression
by turnover of methylation [11] .T h u s ,i ti sp o s s i b l et h a tt h e
5-hmCreductionin cancerouscolorectaltissuesdamagesthe
reactivation of these genes through 5-hmC-mediated methy-
lation turnover, which would help the cancer cells to escape
fromtumorsuppressionandapoptosiscausedbyproductsof
these genes. How 5-hmC isdecreased in cancerouscolorectal
tissues is still unclear. It is worth exploring whether it could
be due to decreased 5-hmC production resulting from a
decrease in TET proteins or mutation of these proteins [13,
14] and whether it could be more likely due to an increase in
enzymatic removal orconversion of5-hmC in cancertissues.
In addition, 5-hydroxymethylcytosine DNA-glycosylase that
removes 5-hmC which was found in mammalian tissue [15]
may also abundantly exist in cancerouscolorectal tissues and
contribute to a decrease in 5-hmC.
5.Conclusion
To the best of our knowledge, this is the ﬁrst paper of 5-hmC
distribution in diﬀerent human tissues and 5-hmC status in
solid tumor. It warrants on further investigation of 5-hmC
states in colorectal cancer by using a large quantity of sam-
ples. It would also be necessary to determine 5-hmC states
in other cancer types derived from 5-hmC abundant tissues
such as brain and liver and more widely in other epigenetic-
associated diseases such as neurodegenerative disorders.
5-hmC determination would help to further understand
methylation/demethylation regulation in the formation and
development of epigenetic-associated diseases, thereby ben-
eﬁting diagnostics and therapeutics at early stages of these
diseases.
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